| WHO WE ARE

Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company founded in Nanjing by a team of senior U.S.-trained antibody drug developers.
Since 2014, Our extensive R&D pipeline consist of more than twenty novel tumor immunotherapy molecules based on monoclonal and bispecific antibody technology platforms.
2014
nanjing R&D center Established
80
%+
Proportion of R&D Personnel​​​​​​​
20
+
R&D Pipeline
10
+
Issued Patents​​​​​​​
RESEARCH AND DEVELOPMENT​​​​​​​
  • Clinical Project
    Focus on discovery and development of novel antibody drugs with independent intellectual property rights for the treatment of oncology and other major diseases of high unmet medical needs.
  • R&D Pipeline
    Our extensive R&D pipeline consist of more than twenty novel tumor immunotherapy molecules.
  • Innovative Platforms
    Providing safe, effective, accessible and affordable new drugs based on monoclonal and bispecific antibody technology platforms.
LATEST NEWS

NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma

NANJING, China, July 31, 2023--Nanjing Leads Biolabs Co.,Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investigational New Drug (

no photo
The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

no photo
Leads Biolabs Announces Updated Results for LBL-007 to be Presented at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

NANJING, China, June 1, 2023--Nanjing Leads Biolabs Co.,Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the latest updated clinical data on the safety and efficacy of its anti-LAG-3 (lymphocyte activating gene-3) antibody LBL-007 and toripalimab combination therap

no photo

Projects and Pipelines

Contact Us
Leads Biolabs © Nanjing Leadsbiolabs  Co., Ltd. | Su ICP No. 18069235-1​​​​​​
Privacy Policy